| Market Cap | $83.83M+16.1% |
| Revenue (ttm) | $105.21M |
| Net Income | -$27.08M |
| EPS | -$2.69 |
| Shares Out | 11.09M |
| PE Ratio | n/a |
| Forward PE | -34.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 205,366 |
| Open | $8.17 |
| Previous Close | $8.30 |
| Day's Range | $7.50 - $8.45 |
| 52-Week Range | $5.26 - $31.97 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | $32.17(+325.49%) |
| Earnings Date | Nov 5, 2026 |
About BDSX
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating BDSX in the last 3 months, one vote each. Issuer-paid research is not counted.
$BDSX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BDSX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BDSX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BDSX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BDSX Revenue by Segment
| Diagnostic Tests | $23.05M | 95.90% |
| Development Services | $986.00K | 4.10% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BDSX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BDSX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from BDSX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings miss and guidance cut drive bearish tone; insider buying and conference presentation provide modest support but cannot offset negative fundamentals.
